JENTADUETO® (linagliptin/metformin HCl) : Demonstrated safety and tolerability profile across a broad range of T2D patients1.


The safety of linagliptin 2.5 mg twice daily (or its bioequivalent of 5 mg once daily) in combination with metformin has been evaluated in over 6,800 patients with T2D1.